{
    "organizations": [],
    "uuid": "4925bc3c87f495a17cedc11e9a883ed5e9395bd5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-xbrane-biopharma-signs-license-agr/brief-xbrane-biopharma-signs-license-agreement-in-china-idUSFWN1PW07A",
    "ord_in_thread": 0,
    "title": "BRIEF-Xbrane Biopharma Signs License Agreement In China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - XBRANE BIOPHARMA AB:\n* REG-XBRANE BIOPHARMA SIGNS LICENSE AGREEMENT WITH CR PHARMA FOR SPHEROTIDE IN CHINA\n* ‚ÄçWILL RECEIVE A LICENSE FEE IN HIGH SINGLE DIGIT MILLION USD RANGE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-06T16:44:00.000+02:00",
    "crawled": "2018-02-07T21:52:01.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "xbrane",
        "biopharma",
        "ab",
        "biopharma",
        "sign",
        "license",
        "agreement",
        "cr",
        "pharma",
        "spherotide",
        "china",
        "receive",
        "license",
        "fee",
        "high",
        "single",
        "digit",
        "million",
        "usd",
        "range",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}